Glaukos to Release Second Quarter 2024 Financial Results after Market Close on July 31Business Wire • 07/10/24
Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common StockBusiness Wire • 06/14/24
Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1Business Wire • 04/10/24
Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)Business Wire • 04/03/24
Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual MeetingBusiness Wire • 04/01/24
Glaukos to Release Fourth Quarter and Full Year 2023 Financial Results after Market Close on February 21Business Wire • 01/31/24